In invasive infection models (systemic infection and pneumonia), all tested AMPs reduced the mortality and bacterial load of MDR-Ab, except for melittin, which was unable to improve these factors after intraperitoneal administration in a systemic infection model [26]. Here, ADSL is linked to pneumonia.